The level of genetic mutations in a tumor, called tumor mutational burden (TMB), has been used to predict how people with cancer will respond to immunotherapy. But MSK physician-scientist Luc Morris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback